• Molecular NameEzetimibe
  • SynonymNA
  • Weight409.432
  • Drugbank_IDDB00973
  • ACS_NO163222-33-1
  • Show 3D model
  • LogP (experiment)4.584
  • LogP (predicted, AB/LogP v2.0)4.26
  • pkaN/A
  • LogD (pH=7, predicted)4.26
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-5.05
  • LogSw (predicted, AB/LogsW2.0)0.01
  • Sw (mg/ml) (predicted, ACD/Labs)0.0
  • No.of HBond Donors2
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds6
  • TPSA60.77
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn anti-hyperlipidemic medication that is used to lower cholesterol levels.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability50.0
  • Protein binding90.0
  • Volume of distribution (VD)1.5 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmIntestinal wall, hepatic. Ezetimibe is extensively metabolized to a glucuronide, which is more active than ezetimibe in inhibiting cholesterol absorption
  • Half life28~30 h
  • ExcretionRenal 11%, faecal 78%
  • Urinary Excretion2
  • Clerance6.6 ml/min/kg
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A